Advances in the HIF-1α/p300 protein-protein interaction inhibitors

MO Xiaofei; XU Xiaoli; WANG Yalou; YOU Qidong

doi:10.11665/j.issn.1000-5048.20170502

Journal of China Pharmaceutical University > 2017 > 48(5): 515-522. > DOI: 10.11665/j.issn.1000-5048.20170502

MO Xiaofei, XU Xiaoli, WANG Yalou, YOU Qidong. Advances in the HIF-1α/p300 protein-protein interaction inhibitors[J]. Journal of China Pharmaceutical University, 2017, 48(5): 515-522. DOI: 10.11665/j.issn.1000-5048.20170502

Citation:

PDF (3733 KB)

Advances in the HIF-1α/p300 protein-protein interaction inhibitors

More Information

Graphical Abstract

Abstract

Abstract

Hypoxia induced factor-1α(HIF-1α)is a key regulation factor that helps tumor adapt itself to the hypoxia microenvironment. It regulates the expression of more than 100 target genes that control cell proliferation and survival, metabolism, angiogenesis, invasion and metastasis. HIF-1α/p300, a core complex that regulates downstream genes expression, is considered as a potential antitumor target. This review summarizes HIF-1α signal pathway, the binding mode of HIF-1α/p300 protein-protein interaction and recent development on the HIF-1α/p300 protein-protein interaction inhibitors, which provides reference to the design of this kind of inhibitors.
- HIF-1α,
- p300,
- protein-protein interaction,
- antitumor,
- progress

FullText(HTML)

References (30)

References

[1]	Harris AL.Hypoxia—a key regulatory factor in tumor growth[J]. Nat Rev Cancer,2002,2(1):38-47.
[2]	Semenza GL.HIF-1:upstream and downstream of cancer metabolism[J]. Curr Opin Genet Dev,2010,20(1):51-56.
[3]	Arany Z,Huang LE,Eckner R,et al.An essential role for p300/CBP in the cellular response to hypoxia[J]. Proc Natl Acad Sci U S A,1996,93(23):12969-12973.
[4]	Kamei Y,Xu L,Heinzel T,et al.A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors[J]. Cell,1996, 85(3):403-414.
[5]	Vo N,Goodman RH.CREB-binding protein and p300 in transcriptional regulation[J]. J Biol Chem,2001,276(17):13505-13508.
[6]	Majmundar AJ,Wong WJ,Simon MC.Hypoxia-inducible factors and the response to hypoxic stress[J]. Mol Cell,2010,40(2):294-309.
[7]	Xia Y,Choi HK,Lee K.Recent advances in hypoxia-inducible factor(HIF)-1 inhibitors[J]. Eur J Med Chem,2012,49:24-40.
[8]	Semenza GL.Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics[J]. Oncogene,2010,29(5):625-634.
[9]	Semenza GL.Targeting HIF-1 for cancer therapy[J]. Nat Rev Cancer,2003,3(10):721-732.
[10]	Semenza GL.Hypoxia-inducible factors in physiology and medicine[J]. Cell,2012,148(3):399-408.
[11]	Freedman SJ,Sun ZY,Poy F,et al.Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha[J]. Proc Natl Acad Sci U S A,2002,99(8):5367-5372.
[12]	Shimoda LA, Semenza GL. Functional analysis of the role of hypoxia-inducible factor 1 in the pathogenesis of hypoxic pulmonary hypertension[J]. Methods Enzymol,2004,381(1):121-129.
[13]	Dames SA,Martinezyamout M,De Guzman RN,et al.Structural basis for Hif-1 alpha /CBP recognition in the cellular hypoxic response[J]. Proc Natl Acad Sci U S A,2002,99(8):5271-5276.
[14]	Kyle HF,Wickson KF,Stott J,et al.Exploration of the HIF-1α/p300 interface using peptide and Adhiron phage display technologies[J]. Mol Biosyst,2015,11(10):2738-2749.
[15]	Henchey LK, Kushal S, Dubey R, et al. Inhibition of hypoxia inducible factor 1 transcription coactivator interaction by a hydrogen bond surrogate α-helix[J]. J Am Chem Soc,2009,132(3):941-943.
[16]	Kushal S,Lao BB,Henchey LK,et al.Protein domain mimetics as in vivo modulators of hypoxia-inducible factor signaling[J]. Proc Natl Acad Sci U S A,2013,110(39):15602-15607.
[17]	Burslem GM,Kyle HF,Breeze AL,et al.Small-molecule proteomimetic inhibitors of the HIF-1α-p300 protein-protein Interaction[J]. ChemBioChem,2014,15(8):1083-1087
[18]	Lao BB, Grishagin I, Mesallati H, et al. In vivo modulation of hypoxia-inducible signaling by topographical helix mimetics[J]. Proc Natl Acad Sci U S A,2014,111(21):7531-7536.
[19]	Cook KM,Hilton ST,Mecinovi'c J,et al.Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1α(HIF-1α)and p300 by a zinc ejection mechanism[J]. J Biol Chem,2009,284(39):26831-26838.
[20]	Block KM,Wang H,Szabo LZ,et al.Direct inhibition of hypoxia-inducible transcription factor complex with designed dimeric epidithiodiketopiperazine[J]. J Am Chem Soc,2009,131(50):18078-18088.
[21]	Reece KM,Richardson ED,Cook KM,et al.Epidithiodiketopiperazines(ETPs)exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer[J]. Mol Cancer,2014,13(1):91.
[22]	Jayatunga MK,Thompson S,McKee TC,et al.Inhibition of the HIF1α-p300 interaction by quinone-and indandione-mediated ejection of structural Zn(II)[J]. Eur J Med Chem,2015, 94:509-516.
[23]	Na YR,Han KC,Park H,et al.Menadione and ethacrynic acid inhibit the hypoxia-inducible factor(HIF)pathway by disrupting HIF-1α interaction with p300[J]. Biochem Biophys Res Commun,2013,434(4):879-884.
[24]	Wu D,Zhang R,Zhao R,et al.A novel function of novobiocin:disrupting the interaction of HIF 1α and p300/CBP through direct binding to the HIF-1α C-terminal activation domain[J]. PLoS ONE,2013,8(5):e62014.
[25]	Kwon HS,Kim DR,Yang EG,et al.Inhibition of VEGF transcription through blockade of the hypoxia inducible factor-1α-p300 interaction by a small molecule[J]. Bioorg Med Chem Lett,2012,22(16):5249-5252.
[26]	Mooring SR,Jin H,Devi NS,et al.Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway[J]. J Med Chem,2011,54(24):8471-8489.
[27]	Mun J,Jabbar AA,Devi NS,et al.Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl] heteroarylsulfonamides,novel,small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents[J]. J Med Chem,2012,55(15):6738-6750.
[28]	Shi Q,Yin S,Kaluz S,et al.Binding model for the interaction of anticancer arylsulfonamides with the p300 transcription cofactor[J]. ACS Med Chem Letters,2012,3(8):620-625.
[29]	Wang W,Ao L,Rayburn ER,et al.KCN1,a novel synthetic sulfonamide anticancer agent:in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology[J]. PLoS ONE,2012,7(9):e44883.
[30]	Liu F,Sun HP,You QD.Advances in small-molecule inhibitor targeting Hsp 90-Cdc37 protein-protein interaction[J].J China Pharm Univ(中国药科大学学报),2015,46(3):272-278.

Cited By

Get Citation

PDF

XML

Article views (1152) PDF downloads (2676)

Turn off MathJax

Article Contents

Abstract

References

Advances in the HIF-1α/p300 protein-protein interaction inhibitors

Abstract

References

Catalog

Export File

Citation

Format

Content